|21 September 2016|
General Electric (GE) is to invest €150 million in a new biopharmaceutical manufacturing in Ireland.
Featuring Europe’s first KUBio™, prefabricated, off-the-shelf bio-manufacturing facilities, owned and run by GE customers, GE BioPark Cork will be a key hub for attracting further investment in next-generation biopharmaceutical manufacturing in Ireland.
Kieran Murphy, CEO, GE Healthcare Life Sciences, GE Healthcare said: “Pharma companies world-wide are racing to respond to patient needs with new life-changing biological medicines and GE is investing in technology and service solutions, as well as industry skills and expertise, to enable them to make and get their products to market more quickly. We are delighted to be investing once again in Ireland, where we have ourselves a long history of manufacturing our own medical imaging products.”
Subject to planning approvals, construction is expected to begin mid- 2017 and will take around 18 months.